Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 22 tags : Trial save search
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
Published: 2021-04-22 (Crawled : 21:00) - biospace.com/
ANAB | $21.3 -6.21% -6.62% 270K
|
Health Technology
|
| O: -0.13%
H: 6.67%
C: 0.75%
fda cancer trial approval fda approval dostarlimab
FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Published: 2021-04-22 (Crawled : 21:00) - biospace.com/
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -1.15%
H: 0.36%
C: -0.34%
fda women cancer trial approval granted grant dostarlimab
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed
Published: 2021-04-22 (Crawled : 14:00) - prnewswire.com
ACAD M | $16.89 -1.46% -1.48% 1.1M
|
Health Technology
|
| O: 0.0%
H: 1.26%
C: -2.79%
trial
Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway
Published: 2021-04-22 (Crawled : 14:00) - biospace.com/
HOTH | $1.2 -1.64% -1.67% 55K
|
Health Technology
|
| O: 0.0%
H: 4.58%
C: -0.65%
treatment dermatitis trial atopic dermatitis
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2021-04-22 (Crawled : 13:00) - novocure.com
NVCR | $12.72 -6.26% -6.68% 1.1M
|
Health Technology
|
| O: -0.08%
H: 2.65%
C: -0.61%
fda lung cancer ide approval cancer trial approval fda ide
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
Published: 2021-04-22 (Crawled : 12:00) - globenewswire.com
AKTX | $1.21 12.7% 9.1K
|
Health Technology
|
| O: 2.09%
H: 1.23%
C: -0.41%
presentation disease trial designation
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
Published: 2021-04-22 (Crawled : 12:00) - biospace.com/
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
|
| O: 0.1%
H: 0.64%
C: -0.37%
acne results topline phase 3 trial
CNH Industrial to announce 2021 First Quarter financial results on May 5, 2021
Published: 2021-04-22 (Crawled : 10:00) - globenewswire.com
CNHI | $12.7 0.55% 0.0% 7.5M
|
Producer Manufacturing
|
| O: -0.59%
H: 0.2%
C: -1.32%
financial results results trial
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.